On November 16, 10x Genomics, Inc. fell 5.01% in Regular Trading, trading around $55.46 per share with turnover of $21.729 million.
The move coincided with continued digestion of the company’s latest quarterly results, post-earnings price-target reductions by several firms, and a recently disclosed CEO share sale that continued to pressure near-term sentiment.
In its latest quarterly report, 10x Genomics, Inc. posted a loss of $0.15 per share, better than expectations for a loss of about $0.25 to $0.27, while revenue of $150.667 million topped forecasts near $148 million. The company also raised full-year revenue guidance to $625 million-$635 million, above the market view of $620.8 million. Even so, recent target-price revisions included UBS to $61 from $90, alongside prior cuts cited for Barclays and BofA, indicating valuation pressure remained the dominant market focus.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments